GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Redhill Biopharma RDHL · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.40

-7.69%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Redhill Biopharma

Its shares trade under the ticker RDHL. It has been listed since 7 January 2013. In the fiscal year to 31 December 2025, it reported revenue of $286,000 and a net loss of $429,000. At that date it held total assets of $25.3m and shareholders' equity of $4.3m.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 Jan 2013
Employees
13
Head office
21 HA'ARBA'A STREET, TEL AVIV, L3, 64739
Incorporated in
L3
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • RedHill Biopharma Ltd. develops Talicia for H. pylori infection treatment in adults.
  • The company has five therapeutic candidates in clinical development including opaganib for severe COVID-19 pneumonia.
  • RHB-204 is in Phase 3 clinical trial for pulmonary Mycobacterium avium complex disease treatment.

Weaknesses

  • RedHill Biopharma Ltd. has only 13 employees as of the latest data.
  • The company is listed on the stock market since 7 January 2013.
  • Talicia and Aemcolo are the only commercialized products currently.

Opportunities

  • RHB-107 (upamostat) targets outpatient SARS-CoV-2 treatment and advanced cholangiocarcinoma.
  • Opaganib is being developed for nuclear radiation protection applications.
  • RHB-104 is in development for Crohn's disease treatment.

Threats

  • The company's pipeline includes only five therapeutic candidates in clinical development.
  • RHB-102 (Bekinda) is for acute gastroenteritis and gastritis treatment.
  • The company has no products in the oncology support anti-emetic market segment.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.